Quizartinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute
Trial Timeline
Dec 8, 2016 → Sep 14, 2018
NCT ID
NCT02984995About Quizartinib
Quizartinib is a phase 2 stage product being developed by Daiichi Sankyo for Leukemia, Myeloid, Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT02984995. Target conditions include Leukemia, Myeloid, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772246 | Phase 1 | Completed |
| NCT06740799 | Phase 1 | Recruiting |
| NCT04473664 | Phase 1 | Completed |
| NCT03723681 | Phase 1 | Completed |
| NCT02984995 | Phase 2 | Completed |
Competing Products
20 competing products in Leukemia, Myeloid, Acute